

Development of a Tool for Fully Automatic Model Development (AMD)

PAGE, June 29th, 2022

Xiaomei Chen¹, Alzahra Hamdan¹, Shijun Wang¹, Tianwu Yang¹, Rikard Nordgren¹, Stella Belin¹, Zhe Huang¹, Simon J. Carter¹, Simon Buatois², João A. Abrantes², Andrew C. Hooker¹, Mats O. Karlsson¹

¹Department of Pharmacy, Uppsala University

²*Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland*



UPPSALA
UNIVERSITET



Building a population PK model: iterative manual model fitting

model structure
random effects
RUV model
covariate model
outlier/influential individual

...



Dataset




**Final
model**

Building a population PK model: Automatic Model Development (AMD)




model scope
search algorithm
selection criterion
error handling
results output

...




Dataset



**Final
model**

The **full** AMD tool is based on newly developed methods and our previous tools/methods




Workflow of the full AMD tool




Input

PharmPy: automatic model development



AMD modules in Pharnpy/pharmr can be used in the AMD workflow or separately





Module	Search Algorithm	Selection criterion
Structural model*	Exhaustive stepwise	BIC ¹
IIV model	2-step exhaustive <ul style="list-style-type: none"> • number of etas • omega matrix structure 	BIC ²
RUV model	3-stepwise resmod ³ <ul style="list-style-type: none"> • combined model, power model, IIV on RUV, time varying model 	Likelihood Ratio Test (LRT)
Covariate model	Stepwise covariate model (SCM)	LRT
Allometry	User defined allometric model	-
IOV model	2-step exhaustive	BIC ²
Detecting influential subjects/outliers	Prediction based on artificial neural network	



*For a small molecule PK after oral or i.v. administration

Structural model selection

Search algorithm: exhaustive stepwise





An example with reduced search space



P1: 2-comp model
 Tn: n-transit comp model
 LAG: lag time

IIV model selection

Search algorithm: 2-step exhaustive




selected model in each step based on BIC

[X,Y]: covariance between X and Y

[X]+[Y]: diagonal omega structure


↑
The drop of BIC from last step

RUV model selection: Search algorithm: 3-stepwise resmod



selected model in each step based on p-value of LRT

The questions we want to answer through the initial evaluation

- 
- Can the AMD tool be successfully run on real data?
 - What is the quality of the final model selected by the AMD tool?
 - What is the impact of the selection order?
 - How fast is it?




The AMD tool evaluation on 10 datasets

Drug	Administration	Number of subjects	Number of observations
gentamicin	<i>i.v.</i>	210	574
daunorubicin	<i>i.v.</i>	41	112
factorVIII	<i>i.v.</i>	34	714
pefloxacin	<i>i.v.</i>	74	337
tobramycin	<i>i.v.</i>	155	388
desmopressin	oral	28	373
lopinavir	oral	30	315
melagatran	oral	167	1177
moxonidine	oral	73	1006
warfarin	oral	32	246




3 orders of model selection were tested for the impact of the order


SIR



RSI



SRI




S: Structural model
I: IIV model
R: RUV model

Start model


- structural model: 1-comp model with 1st-order elimination (and 1st-order absorption)
- IIV model: [CL, V] or [CL,V]+[MAT]
- RUV model: proportional model




The 3 orders gave similar BIC



i.v. drugs



oral drugs



- RSI S: structure model
- SIR I: IIV model
- SRI R: RUV model
- *Published model on normal scale data
- +Published model on log scale data


*The modified published models with only model structure, IIV, and RUV
 +Some published models were originally fitted to log-transformed data




The AMD running time:

i.v. drugs 3-10 min; oral drugs: 17 min-6.5 hours

i.v. drugs




oral drugs





Summary of the initial evaluation




Properties of the AMD tool

- Systematic, extensive, objective, flexible, model building
- Requires a good knowledge of relevant model scope
- Allows evaluation and improvement of standard model building practices
- Avoids human coding errors
- Sensitive to software bugs
- Frees modeler's time for other tasks



Development status



Done
Ongoing
To do/Under consideration

Module	Implemented	Initial testing on 10 datasets	Method improvement
Structural model	Done	Done	Additional modules (PKPD etc.)
RUV model	Done	Done	Automatic selection of normal vs log-scale
IIV model	Done	Done	More efficient search algorithm and method; Semi-parametric distributions
IOV model	Done	Ongoing	
Allometry	Done	Ongoing	
Covariate model	Done	Ongoing	More efficient search algorithms and method
Influential subjects/outliers	Done	Ongoing	Allow AMD actions based on such results
AMD workflow with all the modules	Done	Ongoing	Allow more selection criteria; Extensive testing;





Welcome to our AMD posters

- **S-07 Entire meeting** Rikard Nordgren:
 - **Pharmpy**: a versatile open-source library for pharmacometrics
- **IV-30 Thursday 15:00** Alzahra Hamdan
 - Automatic Development of Pharmacokinetic **Structural Models** – Pharmpy Model Search Tool
- **IV-11 Thursday 15:00** Simon Carter
 - The development of artificial neural networks for the prediction of **influential individuals and outlying individuals** and their application during the model building process
- **IV-31 Thursday 15:00** Zhe Huang
 - Comparison of PK models using **normal and log-transformed scale data**
- **I-01 Wednesday 9:45** João A. Abrantes
 - ADaMO: **End-to-end automation of Pharmacometric modelling** in drug development, from dataset building to output generation



If you want to use our AMD and other Pharmpy tools

- Pharm**py**/pharm**r** is available in Python and R
- Download the most recent version:
<https://github.com/pharmpy>
- Pharmpy manual:
<https://pharmpy.github.io>



Acknowledgement for tool testing and feedback

Roche

Emilie Schindler

Franziska Schädeli Stark

Nicolas Frey

Sylvie Retout

Valérie Cosson

This work was supported by F. Hoffmann-
La Roche Ltd., Basel, Switzerland.





Thank you for listening!

Questions?

